Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals

Sandoz K.K., a generic unit of the Novartis group, was the only company to receive approval for generic versions of Novartis Pharma’s angiotensin receptor blocker Diovan (valsartan) in the latest batch of generic approvals, stirring speculation that the products will...read more